이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Evaluation of the Ileo-anal Pouch in FAP (ENDOPOL) (ENDOPOL)

2026년 7월 21일 업데이트: London North West Healthcare NHS Trust

ENDOPOL: Dye chromoENDOscopy Versus Virtual Chromoendoscopy for Assessment of the Ileo-anal Pouch in Patients With Familial Adenomatous POLyposis: a Randomized Controlled Trial

This international, multi-centre randomised controlled trial will compare dye-based chromoendoscopy with virtual chromoendoscopy, using NBI/BLI, for adenoma detection during routine surveillance pouchoscopy in adults with familial adenomatous polyposis (FAP) and an ileal pouch-anal anastomosis (IPAA). The estimated study duration is 2 years. Participants will undergo their usual scheduled pouchoscopy, performed by endoscopists experienced in FAP. Before the procedure, they will be randomised 1:1 to dye-based or virtual chromoendoscopy. Adenomas requiring endoscopic treatment will be removed during the same procedure according to standard practice.

To our knowledge, no previous study has directly compared these techniques in this setting. Current guidelines recommend surveillance in patients with FAP and a pouch and permit dye-spray chromoendoscopy, but do not specify whether dye-based or virtual chromoendoscopy should be preferred. Practice varies between centres: virtual chromoendoscopy is commonly used at St Mark's Hospital, while some European centres primarily use dye-based chromoendoscopy. This study therefore aims to standardise practice and generate evidence to inform future surveillance strategies.

Eligible patients will be adults aged ≥18 years with FAP, defined by a proven APC germline mutation or a clinical diagnosis of >100 colorectal adenomas with a positive family history, and who have undergone IPAA after primary proctocolectomy or secondary proctectomy following IRA/ISA. Patients will be identified through routine endoscopy booking systems. Those who have consented to email communication from the Polyposis Registry team will receive a Participant Information Sheet in advance. They will be approached again on the day of their procedure, given the opportunity to ask questions, and consented before randomisation. Patients who do not consent will undergo their planned pouchoscopy as normal, without study randomisation. Patients lacking capacity to consent will not be approached.

Randomisation will be performed using an independent computer-generated programme within Castor EDC, with allocation in a 1:1 ratio. Block randomisation will ensure balanced distribution between arms within each centre, and stratification by centre will account for differences in patient characteristics and local practice. Blinding is not feasible because dye-based and virtual chromoendoscopy have visually distinct appearances.

During pouchoscopy, the pre-pouch ileum, pouch body and rectal cuff will be carefully inspected. In the dye-based arm, indigo carmine will be applied using a spray catheter before withdrawal and mucosal inspection. In the virtual chromoendoscopy arm, inspection will be performed using NBI/BLI according to local platform availability. The endoscope will be advanced to the pre-pouch ileum, followed by systematic withdrawal and spiral mucosal inspection. Lesions will be documented by size and location, including pouch body and rectal remnant/rectal cuff, using a polyp burden scoring table. Retroflexion will be performed to assess the rectal cuff. Polyp size will be estimated in millimetres, supported where appropriate by biopsy forceps of known size. Adenomas will be resected using standard polypectomy techniques where indicated, including polyps >5 mm in the pouch body, >2 mm in the rectal cuff, or lesions suspicious for high-grade dysplasia or early cancer.

Because assessment of small polyps can vary between endoscopists, particularly for lesions <5 mm, endoscopic images will be used to assess inter-rater and intra-rater reliability for polyp burden and size. If reliability is acceptable, smaller polyps will be included and reported.

Quality parameters will be collected for each procedure, including adjusted Boston Bowel Preparation Scale assessment for the pouch and total procedural time. Procedural time will include scope introduction, irrigation, dye application where applicable, withdrawal and inspection, retroflexion, and removal and retrieval of polyps.

Post-procedure follow-up will follow routine care. Patients will be asked to monitor for adverse events after pouchoscopy and contact the hospital if needed. Future surveillance will be scheduled according to each centre's usual policy.

Study data will be held in routine hospital systems accessible to the patient's usual clinical team and in a study file. Participants will be assigned a study number. No identifiable patient information will leave the Trust or be accessible to anyone outside the usual care team. Anonymised data will be entered into Castor EDC. Pseudonymised data will be transferred to the central study team at Amsterdam University Medical Center under an existing data transfer agreement for pooled analysis.

The study does not expose participants to risks beyond routine surveillance pouchoscopy. There is no direct individual benefit but findings may benefit future patients with FAP and families by improving evidence.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

This study is an international, multicentre, randomised controlled trial comparing dye-based chromoendoscopy with virtual chromoendoscopy during surveillance pouchoscopy in adults with familial adenomatous polyposis and an ileal pouch-anal anastomosis. The anticipated study duration is approximately 2 years.

Following restorative proctocolectomy, adenomas may develop within the ileal pouch, rectal cuff or pre-pouch ileum. Continued endoscopic surveillance is therefore recommended because progressive adenomatous change may be associated with high-grade dysplasia or malignancy. Current surveillance guidelines permit the use of enhanced endoscopic imaging but do not specify a preferred chromoendoscopy technique because comparative evidence in this setting remains limited.

Dye-based chromoendoscopy involves topical application of contrast dye to enhance mucosal surface architecture and lesion margins. Virtual chromoendoscopy uses optical or digital image-enhancement technologies, including narrow-band imaging or blue-light imaging, to improve visualisation of mucosal and vascular patterns without routine application of contrast dye. Both approaches are established in clinical endoscopy, although practice varies between centres. Virtual chromoendoscopy is commonly used at St Mark's Hospital, whereas dye-based chromoendoscopy remains the predominant approach at several other European centres.

No adequately powered randomised study has directly compared dye-based and virtual chromoendoscopy for surveillance of an ileal pouch in familial adenomatous polyposis. The relative ability of each technique to identify clinically relevant adenomas, characterise overall polyp burden and support reproducible lesion measurement therefore remains uncertain. The present study is intended to provide comparative evidence, reduce variation in surveillance practice and inform future recommendations regarding the optimal imaging approach.

Participant identification and enrolment

Potential participants scheduled for clinically indicated surveillance pouchoscopy will be identified by the local clinical team through endoscopy booking systems, polyposis registries or equivalent institutional records. Study information may be provided electronically or by another locally approved method before the planned procedure. Potential participants will have an opportunity to review the study information and raise questions before enrolment.

Final confirmation of eligibility and written informed consent will occur before the surveillance procedure. Participation will not alter the clinical indication for pouchoscopy. Declining participation will not affect the scheduled procedure, subsequent care or future surveillance.

Randomisation will occur after consent and before insertion of the endoscope. The allocated imaging technique will be used during the diagnostic inspection phase of the pouchoscopy.

Randomisation and allocation

Randomisation will be performed through Castor Electronic Data Capture using an independent computer-generated allocation sequence. Allocation will occur in a 1:1 ratio between dye-based chromoendoscopy and virtual chromoendoscopy.

Variable block sizes of 2, 4 and 6 will be used to preserve allocation balance while reducing the predictability of subsequent assignments. Randomisation will be stratified by participating centre to account for potential centre-level differences in participant characteristics, endoscopy platforms, surveillance practices and procedural technique.

The allocation sequence will be concealed within the electronic randomisation system until enrolment and confirmation of eligibility have been completed. Access to the randomisation module will be limited to authorised study personnel at participating centres.

Blinding of the endoscopist is not feasible because dye-based and virtual chromoendoscopy have distinct procedural and visual characteristics. Participant blinding may also be impractical when pouchoscopy is performed under no sedation or mild conscious sedation. Histopathological assessment will be undertaken according to local routine practice, with pathological interpretation based on submitted specimens rather than the assigned endoscopic imaging technique.

Endoscopic procedure

Surveillance pouchoscopy will be performed by endoscopists with experience in familial adenomatous polyposis and ileal pouch surveillance. Procedures will follow local clinical standards and applicable national or European guidance.

The examination will include the pre-pouch ileum, pouch body and rectal cuff or retained rectal mucosa. The endoscope will be advanced to the pre-pouch ileum, followed by systematic withdrawal and circumferential mucosal inspection. A spiral withdrawal technique will be encouraged to maximise visualisation of the mucosal surface. Irrigation and suction will be used as required to remove residual debris, mucus or fluid.

Retroflexion will be performed within the pouch when considered technically feasible and clinically appropriate, allowing detailed inspection of the rectal cuff, anastomosis and distal pouch. Any limitation affecting mucosal visualisation, including inadequate preparation, retained contents, luminal narrowing, inflammation or technical difficulty, will be documented.

Dye-based chromoendoscopy group

In the dye-based chromoendoscopy group, the pre-pouch ileum, pouch body and rectal cuff will be examined following topical application of indigo carmine. Dye will be applied through a spray catheter or another standard endoscopic delivery device.

Application will be sufficiently diffuse to enhance mucosal topography across the relevant anatomical regions. Additional targeted dye application may be undertaken when an area requires closer inspection. Following dye application, the mucosa will be examined systematically during withdrawal of the endoscope.

Indigo carmine functions as a contrast agent by pooling within mucosal grooves and depressions, thereby accentuating surface irregularities and lesion borders. Detection, characterisation and documentation of suspected adenomas will occur during the dye-enhanced inspection phase.

Virtual chromoendoscopy group

In the virtual chromoendoscopy group, the pre-pouch ileum, pouch body and rectal cuff will be examined using narrow-band imaging, blue-light imaging or an equivalent compatible virtual chromoendoscopy mode available on the endoscopy platform at the participating centre.

Virtual chromoendoscopy will be activated during systematic mucosal inspection. White-light imaging may be used for initial orientation, irrigation and identification of anatomical landmarks. The allocated virtual chromoendoscopy mode will then be used for detailed lesion detection and characterisation.

Routine indigo carmine application will not be used during the primary diagnostic inspection in this group. Targeted dye application may only be undertaken when required for clinical safety or management after completion of the allocated diagnostic assessment. Any such use will be recorded as a procedural deviation or additional clinical intervention, as appropriate.

Lesion detection and documentation

All detected lesions will be documented according to anatomical location, estimated size and endoscopic appearance. Location will be recorded separately for the pre-pouch ileum, pouch body and rectal cuff or rectal remnant.

Lesion size will be estimated in millimetres. A closed or open biopsy forceps with known dimensions will be used as a visual reference where appropriate. The largest estimated diameter will be recorded. Standardised study guidance will be provided to reduce variability in the measurement of small lesions.

Polyp burden will be recorded using study-specific scoring tables. Separate assessments will be completed for the pouch body and rectal cuff, with an additional combined assessment representing overall pouch-related polyp burden. The scoring framework will account for lesion number, lesion size and anatomical distribution.

Endoscopic images will be captured for representative lesions and relevant anatomical regions. Images will be obtained in a standardised manner where possible and will include a size reference when technically feasible. Image capture will support central or secondary assessment of lesion size and polyp burden.

Lesions with features suspicious for advanced neoplasia will be documented in detail. Relevant features may include irregular morphology, ulceration, spontaneous bleeding, depression, disrupted vascular pattern, marked surface irregularity or a non-lifting appearance. Management of such lesions will follow established clinical practice and local governance arrangements.

Endoscopic treatment

After completion of the allocated diagnostic inspection and documentation of polyp burden, adenomas meeting criteria for endoscopic treatment will be removed using standard polypectomy techniques.

Indications for polypectomy will include:

  • lesions larger than 5 mm within the pouch body;
  • lesions larger than 2 mm within the rectal cuff or retained rectal mucosa; and
  • lesions with endoscopic features suspicious for high-grade dysplasia or early malignancy.

Removal techniques may include cold biopsy forceps, cold snare polypectomy, hot snare polypectomy or another clinically appropriate method. Selection of the resection technique will depend on lesion size, morphology, location and local practice.

Resected tissue will be retrieved for histopathological examination whenever clinically appropriate. Histological assessment will follow local pathology protocols. Relevant pathological features may include adenomatous histology, grade of dysplasia, completeness of excision where assessable and evidence of invasive malignancy.

Clinical management arising from histopathological findings will remain the responsibility of the treating clinical team and will follow local multidisciplinary pathways.

Reliability assessment

Variation in endoscopic estimation of polyp size and burden may be particularly important for lesions smaller than 5 mm. A structured reliability assessment will therefore be incorporated into the study.

Participating endoscopists will assess a standardised set of endoscopic images showing lesions and representative polyp burden. Each assessor will record lesion size and the corresponding polyp-burden category using the study scoring system.

The same image set will be reassessed after an interval of approximately 1 week. The order of images may be altered during the repeat assessment to reduce recall effects.

Inter-rater reliability will be calculated to quantify agreement between endoscopists. Intra-rater reliability will be calculated to quantify consistency within individual assessors across the two assessment time points. Statistical methods appropriate to the scale and distribution of the measurements will be used, including correlation coefficients, intraclass correlation coefficients or kappa statistics where applicable.

The reliability analysis will inform the interpretation of data relating to small adenomas. Lesions smaller than 5 mm will be included in relevant analyses when measurement and classification demonstrate acceptable reproducibility. Sensitivity analyses may be performed using alternative lesion-size thresholds where reliability is insufficient.

Procedural quality parameters

Standardised quality parameters will be collected for each pouchoscopy. Bowel preparation and mucosal cleanliness will be assessed using an adapted Boston Bowel Preparation Scale suitable for pouchoscopy. Scores will reflect the quality of visualisation within the relevant pouch segments. Additional cleansing performed during the procedure will also be recorded where required by the case report form.

Total procedure duration will be recorded. Procedural time will include endoscope insertion, irrigation, suction, dye application in the dye-based chromoendoscopy group, activation and use of virtual chromoendoscopy, systematic mucosal inspection, retroflexion, lesion documentation, polypectomy, specimen retrieval and endoscope withdrawal.

Factors affecting procedural duration will be documented where relevant, including extensive polyp burden, difficult anatomy, poor preparation, therapeutic intervention or technical equipment issues.

Additional procedural information may include sedation, completeness of examination, depth of insertion into the pre-pouch ileum, use of retroflexion, number of lesions removed, polypectomy technique and immediate adverse events.

Post-procedure management

Immediate post-procedure care will follow routine clinical practice at each participating centre. Participants will receive standard advice regarding symptoms requiring medical review after pouchoscopy or polypectomy.

Potential adverse events may include abdominal pain, bleeding, perforation, post-polypectomy syndrome, sedation-related complications or another clinically significant event. Adverse events identified during the procedure or reported after discharge will be documented and managed according to local clinical pathways and study reporting requirements.

Subsequent surveillance pouchoscopy will be scheduled according to local policy, clinical findings, histopathological results and applicable guidelines. The study allocation will not determine the interval to the next surveillance procedure.

Data collection and management

Study data will be recorded in Castor Electronic Data Capture using standardised electronic case report forms. Each participant will be assigned a unique study identification number.

Data entered into the central study database will not include directly identifying information. The participant identification log linking study numbers to local identifiers will remain securely stored at the recruiting centre and accessible only to authorised personnel.

Source data will remain within routine clinical systems and study files at each participating institution. Relevant source documentation may include endoscopy reports, pathology reports, procedure records, adverse-event documentation and endoscopic images.

Pseudonymised study data will be transferred to the central study team at Amsterdam University Medical Center for data management, pooling and statistical analysis. Data transfer will occur under an applicable data-transfer agreement and in accordance with institutional, national and European data-protection requirements.

Database access will be role-based and password-protected. Data validation checks, range checks and query resolution procedures will be used to support completeness and accuracy. Participating centres may be asked to clarify missing, inconsistent or implausible entries.

Endoscopic images used for reliability or central review will be pseudonymised before transfer. Image files will not contain names, hospital numbers, dates of birth or other direct identifiers.

The final analytical dataset will combine pseudonymised data from participating centres. Statistical analysis will be undertaken according to a prespecified statistical analysis plan. Any protocol deviations affecting allocation, imaging technique, completeness of examination or data integrity will be recorded and considered during analysis.

연구 유형

중재적

등록 (추정된)

50

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

  • 이름: Benjamin Zare, MBChB (Hons) MRCP
  • 전화번호: +442088643232
  • 이메일: b.zare@nhs.net

연구 장소

    • London
      • London, London, 영국, N10 7NS
        • 모병
        • St Mark's Hospital Polyposis Registry (St Mark's Centre for Familial Intestinal Cancer)
        • 연락하다:
        • 연락하다:
          • Benjamin Zare, MBChB (Hons) MRCP
          • 전화번호: +442088643232
          • 이메일: b.zare@nhs.net

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

ALL of the following:

  1. Diagnosis of FAP i.e., at least one of following:

    • Genetic diagnosis: proven APC germline mutation OR
    • Clinical diagnosis: >100 colorectal adenomas in combination with a positive family history of FAP
  2. Have an ileal-pouch anal anastomosis (IPAA), either after primary proctocolectomy or secondary proctectomy after initial colectomy and ileorectal or ileosigmoidal anastomosis (IRA/ISA)
  3. Age ≥ 18 years

Exclusion Criteria:

ANY of the following

  1. Diagnosis of FAP i.e., at least one of following:

    • Genetic diagnosis: proven APC germline mutation OR
    • Clinical diagnosis: >100 colorectal adenomas in combination with a positive family history of FAP
  2. Have an ileal-pouch anal anastomosis (IPAA), either after primary proctocolectomy or secondary proctectomy after initial colectomy and ileorectal or ileosigmoidal anastomosis (IRA/ISA)
  3. Age ≥ 18 years

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 다른
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Chromoendoscopy
Chromoendoscopy arm using dye spray
Chromoendoscopy using dye spray
활성 비교기: Virtual Chromoendoscopy
Virtual chromoendoscopy arm using narrow-band imaging (NBI)
Virtual chromoendoscopy using narrow-band imaging (NBI)

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Incidence of clinically relevant adenomas greater than 5 mm in the ileo-anal pouch
기간: Periprocedural
Incidence of clinically relevant adenomas greater than 5 mm in the ileo-anal pouch comparing dye-based chromoendoscopy with virtual chromoendoscopy using NBI/BLI
Periprocedural

2차 결과 측정

결과 측정
측정값 설명
기간
Incidence of advanced neoplasia in the pouch
기간: Periprocedural
Incidence of advanced neoplasia in the pouch, defined as advanced adenoma ≥10 mm and/or adenoma with high-grade dysplasia, or cancer
Periprocedural
Incidence of adenomas measuring 2-4 mm, 5-9 mm and ≥10 mm
기간: Periprocedural
Incidence of adenomas measuring 2-4 mm, 5-9 mm and ≥10 mm in the pouch body and rectal cuff
Periprocedural
Number of adenomas in the rectal remnant and anal mucosa
기간: Periprocedural
Number of adenomas in the rectal remnant and anal mucosa
Periprocedural
InSiGHT Polyposis Staging System score
기간: Periprocedural
InSiGHT Polyposis Staging System score
Periprocedural
Number of polypectomies performed
기간: Periprocedural
Number of polypectomies performed per procedure
Periprocedural
Length/duration of individual procedures
기간: Periprocedural
Length/duration of individual procedures
Periprocedural
Incidence of endoscopy-related complications
기간: Periprocedural
Incidence of endoscopy-related complications
Periprocedural
Interval between surveillance endoscopies, based on the personalised endoscopic surveillance protocol
기간: From date of randomization until the date of last procedure, assessed up to 60 months
Interval between surveillance endoscopies, based on the personalised endoscopic surveillance protocol used across the European FAP Consortium
From date of randomization until the date of last procedure, assessed up to 60 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Andre Latchford, MBBS PhD FRCP, London North West University Healthcare NHS Trust

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 7월 9일

기본 완료 (추정된)

2031년 7월 9일

연구 완료 (추정된)

2031년 7월 9일

연구 등록 날짜

최초 제출

2026년 7월 10일

QC 기준을 충족하는 최초 제출

2026년 7월 21일

처음 게시됨 (실제)

2026년 7월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 7월 24일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 7월 21일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • RD25/099
  • 365649 (기타 식별자: IRAS Project ID)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Individual participant data will not be made openly available because the study involves a relatively small and potentially identifiable clinical population. Even after de-identification, there may remain a residual risk of re-identification when clinical, demographic, procedural and outcome data are combined. In addition, participants will have consented for their data to be used for the purposes of this study and related ethically approved analyses, rather than for unrestricted external sharing. Requests for access to anonymised aggregate data or specific analyses may be considered by the study team on a case-by-case basis, subject to appropriate ethical, governance and data-sharing approvals.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .